Technology
Health
Biotechnology

Replimune

$14.87
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.40 (2.76%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell Replimune and other stocks, options, ETFs, and crypto commission-free!

About

Replimune Group, Inc. Common Stock, also called Replimune, is a clinical-biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Read More Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in an direct kill turmors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Employees
43
Headquarters
Woburn, Massachusetts
Founded
2015
Market Cap
457.84M
Price-Earnings Ratio
Dividend Yield
Average Volume
83.78K
High Today
$15.00
Low Today
$14.59
Open Price
$14.69
Volume
29.23K
52 Week High
$23.55
52 Week Low
$8.88

Collections

Technology
Health
Biotechnology
Medical
Cancer Prevention
2018 IPO
US
North America

News

BenzingaApr 25

Replimune's Lead Asset Likely To Clear Regulatory Hurdle, Wedbush Says In Bullish Initiation (NASDAQ:REPL)

Replimune Group Inc (NASDAQ: REPL)'s lead asset is expected to quickly pass through development and clear the FDA hurdle, according to Wedbush.

119

Earnings

-$0.40
-$0.34
-$0.29
-$0.23
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
-$0.40 per share
Actual
Expected Jun 13, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.